Zacks Small Cap Issues Negative Outlook for ORMP Earnings

Key Points

• Zacks Small Cap has downgraded Oramed Pharmaceuticals' Q2 2025 earnings per share estimate from ($0.01) to ($0.04), signaling a negative outlook for the biotechnology company.
• Wall Street Zen has also lowered their rating on Oramed Pharmaceuticals from a "hold" to a "sell", indicating growing concerns among analysts.
• Oramed Pharmaceuticals recently reported a quarterly EPS of ($0.19), significantly missing analysts' expectations, and had revenues of $2.00 million for the quarter.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Equities researchers at Zacks Small Cap decreased their Q2 2025 earnings per share (EPS) estimates for shares of Oramed Pharmaceuticals in a research note issued to investors on Monday, July 28th. Zacks Small Cap analyst M. Marin now anticipates that the biotechnology company will earn ($0.04) per share for the quarter, down from their prior forecast of ($0.01). The consensus estimate for Oramed Pharmaceuticals' current full-year earnings is ($0.03) per share. Zacks Small Cap also issued estimates for Oramed Pharmaceuticals' Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.34) EPS.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.16). The company had revenue of $2.00 million during the quarter.

Separately, Wall Street Zen downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th.

Oramed Pharmaceuticals Stock Down 1.4%

Oramed Pharmaceuticals stock traded down $0.03 during mid-day trading on Thursday, hitting $2.12. 61,152 shares of the company's stock were exchanged, compared to its average volume of 67,113. The firm has a market capitalization of $86.60 million, a P/E ratio of -4.82 and a beta of 1.61. Oramed Pharmaceuticals has a fifty-two week low of $1.82 and a fifty-two week high of $3.09. The company's 50 day simple moving average is $2.18 and its 200-day simple moving average is $2.23.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 70,190 shares in the last quarter. BML Capital Management LLC grew its holdings in shares of Oramed Pharmaceuticals by 14.3% in the 1st quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock valued at $6,464,000 after acquiring an additional 376,841 shares in the last quarter. Boothbay Fund Management LLC grew its holdings in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after acquiring an additional 16,857 shares in the last quarter. Peapod Lane Capital LLC grew its holdings in shares of Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after acquiring an additional 24,985 shares in the last quarter. Finally, N.E.W. Advisory Services LLC grew its holdings in shares of Oramed Pharmaceuticals by 52.9% in the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 6,540 shares in the last quarter. Institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.